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Abstract
Melanoma is a skin cancer associated with high mortality. The three year survival rate from advanced melanoma 
is between 10-15%. One reason for this high mortality rate is that melanoma cells are resistant to traditional 
chemotherapeutics. Echinacea is a plant genus native to North America with putative anticancer properties. 
Here, we examined effects of aqueous Echinacea purpurea leaf extract on the growth of melanoma cells and 
nontransformed fibroblasts. This aqueous extract reduced B16 mouse melanoma cell growth at concentrations 
that did not inhibit the growth of nontransformed NIH3T3 fibroblasts, suggesting that the extract had biological 
specificity against transformed cells. We also examined the effect of different fractions of the extract on melanoma 
cell growth. These data indicate that components less than 3 kD in size exhibited the greatest inhibitory action 
on melanoma cell growth. In addition, these data indicated that larger components in the extract ameliorate 
the ability of these low molecular weight compounds to inhibit melanoma cell growth. Furthermore, Echinacea 
extract inhibited the growth of v-Src transformed LA25 cells without reducing Src kinase activity. Taken together, 
these results suggest that aqueous Echinacea purpurea extract contains low molecular weight compounds that 
preferentially inhibit tumor cell growth in the face of oncogenic tyrosine kinase activity. These data suggest future 
studies to better define bioactive compounds in Echinacea purpurea and evaluate their therapeutic efficacy in 
vivo. 
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Introduction
Melanoma is a cancer associated with a high 
mortality rate. The three year survival rate for advanced 
melanoma is only 10-15% [1,2]. A major reason for the 
high mortality is that melanoma cells are resistant to 
standard chemotherapeutic treatments [3,4]. The World 
Health Organization estimates that approximately 
65,000 people die from melanoma worldwide each 
year [5]. New compounds with antineoplastic activity 
against melanoma are urgently needed to treat this 
patient population. 
There is a great interest in phytochemicals for 
melanoma management. Phytochemicals offer fewer 
adverse effects, less toxicity, and lower costs than many 
standard chemotherapy agents [6]. The use of these 
phytochemicals could therefore offer opportunities for 
efficacious therapy for melanoma, and possibly other 
cancers. 
Echinacea is a genus of plant native to eastern 
North America. It was used by Native Americans and 
American settlers for medicinal purposes [7]. There are 
9 species of Echinacea, and 3 are used medicinally. 
These three include Echinacea pallida, Echinacea 
purpurea, and Echinacea angustifolia. Echinacea 
has mainly been used for the homeopathic treatment 
of infections because of its antibacterial and immune 
boosting properties. Echinacea products are currently 
among the bestselling homeopathic remedies in the 
industrialized world [8]. 
Previous studies with organic solvent extracts from 
Echinacea roots or flowers found that Echinacea 
contains components that can reduce colon and 
pancreatic cancer cell growth [9-11]. These studies 
suggested that polyenes [9,10] or cichoric acid [11] are 
biologically active cytotoxic components responsible 
for these effects, and are abundant in these organic 
solvent Echinacea extracts. Studies also indicate that 
Echinacea root ethyl acetate extract is significantly 
more cytotoxic to HeLa cells than hexane extract, 
suggesting that water soluble compounds may play a 
part in Echinacea anticancer effects [12]. Interestingly, 
the use of aqueous extracts of Echinacea leaves, 
were found to be effective in increasing antibody 
response to snake venom [13]. Taken together, these 
studies suggest that aqueous extracts of Echinacea 
may have significant biological activity. It should be 
noted that many anticancer agents need to be given 
via the intravenous route in order to achieve adequate 
efficacy; thus, low water solubility is a barrier to obtain 
an effective chemotherapeutic agent [14].
Here, we report that aqueous extracts of Echinacea 
purpurea leaves had greater inhibitory action on 
melanoma cells than on nontransformed fibroblasts. 
Furthermore, we report that aqueous Echinacea 
purpurea extract contains low molecular weight 
compounds (<3 kD) that inhibited melanoma cell 
growth. The inhibitory activity of this low molecular 
weight fraction was greater than unfractionated extract. 
We also show that aqueous Echinacea purpurea 
extracts inhibited cell growth of Src transformed cells 
without affecting Src kinase activity. These data suggest 
that Echinacea purpurea leaves contain low molecular 
weight compounds that may be useful to combat 
melanoma, and possibly other cancers.
Materials and Methods
Echinacea purpurea aqueous extract 
preparation
Dried Echinacea purpurea leaves were incubated with 
10 volumes (w/v) of 100°C water for 20 minutes and 
cooled to room temperature. This 10% solution was then 
clarified by centrifugation, sterilized by filtration through 
0.2 micron filters (Millipore), frozen, and lyophilized to 
dryness. The dried extract was suspended in distilled 
water to a final concentration of 50 mg/ml.
Extract Fractionation
To examine bioactivity of different sized components 
of Echinacea, aqueous extract was fractionated as 
previously described [15]. Briefly, components greater 
than 50 kD were concentrated by filtering over centrifugal 
membranes with a 50 kD nominal molecular weight 
pore size (EMD Millipore Amicon UFC5050). Filtrates 
were subsequently concentrated over centrifugal 
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membranes with a 3 kD nominal molecular weight pore 
size (EMD Millipore Amicon UFC5003) to concentrate 
components between 3 and 50 kD, and obtain material 
below 3 kD as filtrates. Sizes of the different fractions 
were confirmed by electrophoresis on 4-18% SDS 
gels stained with SilverQuest dye (Invitrogen LC6070). 
Concentrated material, filtrate, and unfractionated 
extract were diluted to achieve final concentrations 
equivalent to 2 mg/ml of original unfractionated extract 
for cell culture studies.  
Evaluation of cell growth 
Cell growth was analyzed as previously described 
[15]. Briefly, B16F10 mouse melanoma cells and 
nontransformed NIH3T3 cells were maintained in 
DMEM (Hyclone SH30021) supplemented with 25 mM 
HEPES (Hyclone SH3027) and FBS (Seradigm 1400-
500) at 37°C in 5% CO2 and 100% humidity [16-20]. 
Effects of aqueous Echinacea extract on cell viability 
were measured by plating 5,000 cells in each well, 
growing them overnight on standard 24 well tissue 
culture plates, and then treating them for 72 hours with 
the aqueous extract of Echinacea. Cells were analyzed 
on an inverted Zeiss Axiovert microscope and counted 
from images with the aid of Zeiss Axiovision software 
as previously described [15,18,19]. In fractionation 
studies, wells were trypsinized and cells removed and 
counted with the Coulter Counter (Beckman Coulter 
Z1 particle counter). LA25 cells were grown overnight 
at non-permissive temperature (40°C) before being 
incubated for 24 hours at permissive (33°C) and non-
permissive (40°C) temperatures [16,17] with or without 
Echinacea extract, and then stained with Trypan blue to 
distinguish living and dead cells. 
Western blotting
Protein was extracted from LA25 cells grown 
at permissive (33°C) and non-permissive (40°C) 
temperatures. The extracted protein was analyzed by 
Western blotting to detect total v-Src (Millipore 05-
185), active Src (p-Src; phosphorylated at tyrosine 
416) (Millipore 04-857), and ß-actin (Sigma A1978) as 
previously described [15-18].
Statistical analyses
Data was analyzed by one way ANOVA using 
GraphPad Prism V. Differences between groups 
were then tested using Bonferroni’s post hoc test of 
significance and p<0.05 was considered significant.
Results
Aqueous Echinacea purpurea extract 
inhibits melanoma cell growth 
Aqueous extracts of Echinacea substantially reduced 
B16 melanoma cell growth after 72 h. This effect was 
more pronounced in melanoma cells than in non-
transformed NIH3T3 fibroblasts. As shown in Figure 
1, all concentrations of Echinacea extract (1, 2, 8 mg/
ml) inhibited melanoma cell growth. For example, 1 
mg/ml extract inhibited growth by 86% and 8 mg/ml 
inhibited growth by 96%. In contrast, 1 mg/ml extract 
did not significantly reduce the growth of NIH3T3 
cells. Only the highest concentration 8 mg/ml reduced 
nontransformed fibroblast growth by 69%.
Different molecular weight fractions 
have different biological activities on 
melanoma cell growth
Echinacea extract was fractionated by molecular 
weight, and different molecular weight fractions 
were added to melanoma cell cultures. All fractions 
significantly reduced cell growth. The largest 
molecular weight fraction (> 50 kD) inhibited growth by 
approximately 54% as shown in Figure 2. However, this 
level of inhibition was less than that of the unfractionated 
extract which reduced cell growth by 87%. Interestingly, 
the <3 kD fraction reduced cell growth by 97%, which 
was significantly more than the intact, unfractionated 
extract.
Echinacea extract inhibits Src 
transformed cell growth, but without 
inhibiting oncogenic Src kinase activity
We utilized LA25 cells transformed by a temperature 
sensitive oncogenic Src kinase construct to investigate 
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Figure 1: Aqueous Echinacea purpurea extract inhibits melanoma cell growth.
Nontransformed NIH3T3 fibroblasts and B16F10 melanoma cells (5,000 cells per well) were grown overnight 
before being incubated for 72 hours with indicated concentrations of Echinacea extract and counted in a 
500×500 micron area in the center of each well. Only the highest concentration of aqueous Echinacea extract 
inhibited growth of NIH 3T3 fibroblasts. In contrast, all concentrations of Echinacea extract reduced melanoma 
cell (B16F10) growth. Data are presented as mean+SEM (n=3). Single and double asterisks denote p<0.05 and 
p<0.01 compared to untreated control cells, respectively. These data are representative of experiments that have 
been repeated with similar results.
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the effects of Echinacea extract on Src transformed 
cells and kinase activity [15,16]. Echinacea aqueous 
extract selectively inhibited Src kinase transformed 
cells grown at permissive temperature as shown in 
Figure 3a. However, this treatment did not decrease Src 
kinase activity of these cells as seen in Figure 3b. 
Discussion
Results from this study indicate that aqueous extract 
of Echinacea purpurea can reduce melanoma cell 
growth. At lower concentrations (1-2 mg/ml), the 
aqueous extract reduced melanoma cell growth without 
significantly inhibiting growth of nontransformed 
fibroblasts. Additionally, different molecular weight 
fractions of Echinacea extract inhibited melanoma 
growth to different extents. Components less than 
3 kD show greater inhibitory activity than the intact 
unfractionated extract, while fractions above 50 kD 
in molecular weight showed less activity than the 
unfractionated extract.
This study presents the novel finding that 
concentrations of aqueous Echinacea extract can 
selectively inhibit melanoma cell growth. These findings 
are consistent with previous reports of Echinacea 
components with anticancer effects [9-11]. However, 
this current study examined the effects of aqueous 
extract while previous studies examined the effects of 
organic solvent extracts on cell growth. In addition, the 
present studies examined the effect of Echinacea on 





















Figure 2: Different fractions of Echinacea extract inhibit melanoma cell growth.
Fractionated and unfractionated Echinacea extract were diluted to concentrations equivalent to 2 mg/ml of 
starting material and incubated with B16F10 melanoma cells for 72h. Cells were then removed from wells by 
trypsin and counted by Coulter counter. All fractions and unfractionated extract inhibited cell growth. The >50 kD 
fraction inhibited cell growth by 54%. This level of inhibition was less than that of the unfractionated extract which 
reduced cell growth by 87%. In addition, the <3 kD fraction reduced cell growth by a significantly greater extent 
than unfractionated extract (97% versus 87% respectively). Data are presented as mean+SEM (n=3). Single 
and double asterisks denotes p<0.05 and p<0.01 compared to untreated control cells and between groups as 
indicated. These data are representative of experiments have been repeated with similar results.
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Figure 3: Effects of Echinacea extract on Src transformed cells and kinase activity.
LA25 cells were grown overnight at non-permissive temperature (40oC). Cells were then incubated at 
nonpermissive (40oC) or permissive (33oC) temperatures with different concentrations of aqueous Echinacea 
extract for 24 h as indicated. Cells were then stained with Trypan blue to measure cell death. (a) The highest 
concentration (4 mg/ml) of Echinacea extract significantly inhibited transformed cell growth at permissive 
temperature, but not non-permissive temperature. Data are shown as mean+SEM (n=3) with single asterisk 
indicating p<0.05. (b) LA25 cells grown at non-permissive and permissive temperatures were incubated with and 
without 4 mg/ml Echinacea aqueous extract. Protein was extracted and examined by western blotting to detect 
total v-Src, active Src (p-Src), and β-actin as indicated. 
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actions of Echinacea on other cancers including colon 
and pancreatic carcinoma cells [9-11]. 
Previous studies suggest that cichoric acid is a 
possible anticancer component found in Echinacea 
[11]. Although cichoric acid is soluble in water and is 
less than 3kD in molecular weight, it is rapidly oxidized 
when Echinacea purpurea is extracted in water [21]; 
therefore, it is unlikely that this compound is the active 
component in the aqueous extract of Echinacea used 
here. Other studies suggest that polyacteylenes and 
polyenes extracted by hexane are active anticancer 
components of Echinacea [10]. These agents are not 
very water soluble and, therefore, are also unlikely to be 
active agents in aqueous extracts examined here. 
Our studies also found that low molecular weight (<3 
kD) compounds inhibited melanoma cell growth more 
than the unfractionated extract. In addition, the >50 
kD fraction showed a significantly lower effect than 
the unfractionated extract. These results suggest that 
fractions with larger compounds (>50 kD) may contain 
molecules which modulate the inhibitory properties 
of the lower molecular weight (<3 kD) fraction. These 
results are different from those of aqueous hibiscus 
flower extract in which unfractionated extract inhibits 
melanoma cell growth more than fractionated material. 
Thus, Echinacea and hibiscus appear to work by 
different mechanisms: Echinacea, contains small 
bioactive compounds less than 3 kD in size, while 
Hibiscus contains active components that work in 
concert for optimum effect [15]. 
The Src tyrosine kinase has been shown to be 
involved in transformation, growth, and metastasis of 
many types of cancer including melanoma [22-26]. 
Our studies indicate that Echinacea extract inhibited 
Src transformed cell growth without affecting Src 
kinase activity in these cells. These data suggest that 
Echinacea extract reduces growth by a mechanism that 
is downstream or independent of Src kinase activity. 
These studies suggest that aqueous Echinacea 
purpurea extract contains compounds that may be 
used as agents to prevent or treat melanoma, and 
possibly other cancers. Interestingly, low molecular 
weight compounds (<3 kD) inhibited transformed cell 
growth to a greater extent than unfractionated extract. 
Future investigations may be performed to identify 
these specific bioactive compounds and elucidate their 
modes of action, as well as their efficacy in vivo.   
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